Clinical Trial Update: Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

View source ↗

Summary

A long-term safety study of Orfadin (nitisinone) in patients with hereditary tyrosinemia type I in standard clinical care has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Tyrosinemia Type

Drugs mentioned

• Orfadin (nitisinone)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Hereditary Tyrosinemia, Type I | Status: COMPLETED